Search research articles
Contact Us
Filters
Showing results (31-40 of 186) with videos related to
Page
of 19
Sort By:
Clinical Lymphoma, Myeloma & Leukemia
|
February 24, 2019
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Gilles Salles, Ajay K Gopal, Monique C Minnema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 17, 2008
Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose
Joseph G Rajendran, Ajay K Gopal, Darrel R Fisher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes
Joseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 8, 2017
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
Abby E Floeter, Amila Patel, Melinda Tran, et al.
Blood Advances
|
January 4, 2018
Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation
Ang Li, Chris Davis, Qian Wu, et al.
Experimental Hematology
|
January 25, 2017
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications
Elahe A Mostaghel, Paul S Martin, Stephen Mongovin, et al.
Blood
|
May 22, 2012
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen, Joycelynne M Palmer, Sandra H Thomas, et al.
Anti-Cancer Drugs
|
August 4, 2015
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation
Andrew J Cowan, Shani L Frayo, Oliver W Press, et al.
Nuclear Medicine Communications
|
September 8, 2012
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes
Naoya Hattori, Ajay K Gopal, Andrew T Shields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2005
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
Herschel Wallen, Theodore A Gooley, H Joachim Deeg, et al.
Page
of 19
Search research articles
Search
Showing results (31-40 of 186) with videos related to
Sort By:
Page
of 19
Clinical Lymphoma, Myeloma & Leukemia
|
February 24, 2019
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Gilles Salles, Ajay K Gopal, Monique C Minnema, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 17, 2008
Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ receiving the highest dose
Joseph G Rajendran, Ajay K Gopal, Darrel R Fisher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 8, 2004
High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes
Joseph G Rajendran, Darrell R Fisher, Ajay K Gopal, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 8, 2017
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy
Abby E Floeter, Amila Patel, Melinda Tran, et al.
Blood Advances
|
January 4, 2018
Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation
Ang Li, Chris Davis, Qian Wu, et al.
Experimental Hematology
|
January 25, 2017
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications
Elahe A Mostaghel, Paul S Martin, Stephen Mongovin, et al.
Blood
|
May 22, 2012
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen, Joycelynne M Palmer, Sandra H Thomas, et al.
Anti-Cancer Drugs
|
August 4, 2015
Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation
Andrew J Cowan, Shani L Frayo, Oliver W Press, et al.
Nuclear Medicine Communications
|
September 8, 2012
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes
Naoya Hattori, Ajay K Gopal, Andrew T Shields, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 13, 2005
Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older
Herschel Wallen, Theodore A Gooley, H Joachim Deeg, et al.
Page
of 19